HK Stock Market Move | LIFETECH SCI(01302) rose more than 4% in the closing session, and the CS stent system has entered the Innovative Medical Management special review procedure.

LIFETECH SCI (01302) rose by more than 4% in the final trading session, with a 4.07% increase at 1.79 Hong Kong dollars by the time of publication, with a trading volume of 37.7646 million Hong Kong dollars. On the news front, on January 9th, the Concave Supra integrated arch three-branch reconstruction system jointly developed by Professor Shu Chang of Fuwai Hospital of the Chinese Academy of Medical Sciences' National Cardiovascular Center and LIFETECH SCI was approved by the National Medical Products Administration and entered the Innovative Medical Management Device Special Review Program, the national innovation "green channel". It is reported that CS stent system is the 17th independently developed innovative product approved to enter the national innovation "green channel" by LIFETECH SCI. Public information shows that this product is suitable for minimally invasive treatment of complex aortic arch aneurysms and penetrating ulcers, and is the world's first minimally invasive aortic arch three-branch reconstruction solution without cerebral ischemia. This product, along with the aortic arch branch reconstruction chimney technology innovation product matrix, the aortic arch branch reconstruction in situ fenestration technology innovation product matrix and the SureCham single branch stent system, jointly constitute LIFETECH SCI's unique overall solution for intracavitary treatment of aortic arch lesions.